Heron Therapeutics
HRTX
151 hedge funds and large institutions have $192M invested in Heron Therapeutics in 2023 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 45 increasing their positions, 38 reducing their positions, and 18 closing their positions.
1,289% more call options, than puts
Call options by funds: $2.19M | Put options by funds: $158K
67% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 18
57% more capital invested
Capital invested by funds: $122M → $192M (+$70M)
18% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 38
7% more funds holding
Funds holding: 141 → 151 (+10)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
8.86% less ownership
Funds ownership: 84.11% → 75.24% (-8.9%)
Top Buyers
| 1 |
O
OrbiMed
New York
|
+$5.64M |
| 2 |
TC
Tejara Capital
London,
United Kingdom
|
+$3.49M |
| 3 |
Renaissance Technologies
New York
|
+$1.75M |
| 4 |
MAM
Monaco Asset Management
Monaco
|
+$1.68M |
| 5 |
CPC
Congress Park Capital
Saratoga Springs,
New York
|
+$1.33M |
Top Sellers
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$8.38M |
| 2 |
JP Morgan Chase
New York
|
-$7.42M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$4.88M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$2.15M |
| 5 |
BlackRock
New York
|
-$1.06M |
HRTX Hedge Fund Activity: Q4 2023 in Review
151 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q4 2023, worth a combined $192M — up 57% from $122M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new HRTX positions and 18 closed out — a net gain of 12 holders — while 45 added to existing stakes and 38 trimmed.
The largest buyer was OrbiMed, adding an estimated $5.64M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $8.38M sold.
- 151 institutional investors held Heron Therapeutics (HRTX) as of Q4 2023, up from 141 in Q3 2023.
- Funds reported $192M of Heron Therapeutics stock for Q4 2023, up 57% quarter-over-quarter.
- 30 funds opened new Heron Therapeutics positions in Q4 2023 and 18 closed out, a net change of +12 holders.
- The largest Heron Therapeutics buyer in Q4 2023 was OrbiMed, an estimated $5.64M added.
- The largest Heron Therapeutics seller in Q4 2023 was Baker Bros. Advisors, an estimated $8.38M sold.
Based on aggregated 13F filings for Q4 2023.